Condition: Glioblastoma Multiforme · Sponsor: UNC Lineberger Comprehensive Cancer Center
The purpose of this study is to test the safety of using T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (CAR.B7-H3T cells) in patients with glioblastoma. CAR.B7-H3T cells treatment has not been tested in humans and is not an approved treatment by the Food and Drug Administration for glioblastoma.
This description comes directly from the study's public registry record.
Catherine Cheng · 919-445-4208 · UNCImmunotherapy@med.unc.edu
Caroline Babinec · 919-962-7426 · UNCImmunotherapy@med.unc.edu
Always discuss trial participation with your own doctor first.
| Lineberger Comprehensive Cancer Center | Chapel Hill, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05366179